Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Eli Lilly’s chief scientific officer said the company purchased a cancer drug from the startup Scorpion Therapeutics because ...

Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A. Ricks, Lilly chair and CEO, will participate in a fireside chat on ...

Eli Lilly and Co., which cemented its place in ... life science firms presenting at J.P. Morgan As part of the deal, Scorpion is going to undergo a shakeup. The Boston biotech is going to spin ...

JPMorgan analyst Chris Schott says Eli Lilly’s (LLY) Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidance ...

such as Eli Lilly's Zepbound or Novo Nordisk's Wegovy -- they've made headlines as demand for them soared. The obesity drug market may reach beyond $100 billion by 2030, according to Morgan ...